---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-003205"
form_type: "8-K"
ticker: "IMRX"
cik: "0001790340"
company_name: "Immuneering Corp"
filed_at: "2022-03-10T23:59:59+00:00"
generated_at: "2026-06-27T00:04:39.393604+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Immuneering reports $150.2M cash; IND for IMM-1-104 expected Q3 2022

## Summary
- Net loss Q4 2021: $10.8M ($0.42/share) vs $5.8M ($1.18/share) Q4 2020; full year loss $33.5M.
- Cash and equivalents $150.2M as of Dec 31, 2021; expected cash runway into Q3 2024.
- 2022 GAAP operating expense guidance $55M-$60M; includes non-cash stock-based compensation.
- IMM-1-104 IND filing expected Q3 2022, first patient enrollment in Phase 1 trial Q4 2022.
- IMM-6-415 designated as drug candidate; IND-enabling studies underway, filing expected 2023.

## SEC filing metadata
- accession: 0001558370-22-003205
- form_type: 8-K
- ticker: IMRX
- cik: 0001790340
- company_name: Immuneering Corp
- filed_at: 2022-03-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1790340/000155837022003205/0001558370-22-003205-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1790340/000155837022003205/imrx-20220310x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-003205
- JSON: https://secwatch.observer/filing/0001558370-22-003205.json
- Plain text: https://secwatch.observer/filing/0001558370-22-003205.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.